Insider trade

Gilead Sciences (GILD): Officer sold ~$133K

Johanna Mercier, Officer at Gilead Sciences, sold ~$133K of Gilead Sciences shares.

~$133K
Approx. value · 1,070 sh @ $124.00
125K
Holds after · shares reported
Traded
Jun 15, 2026
Filed
Jun 16, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 27, 2026CongressDisclosed purchase of GILD — reported range $1,001 - $15,000
  2. Apr 15, 2026Insider · 2 peopleInsiders: 2 sales (~$846K)
  3. Apr 28, 2026Insider · 1 personInsiders: 2 sales (~$1.3M)
  4. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  5. Apr 30, 2026Layoff notice · 800 Bridge Parkway Redwood City CA 94065Layoff notice filed in CA: 108 employees
  6. May 6, 2026Congress · 1 personMembers of Congress: 2 purchases
  7. May 7, 2026Company filing · Form 8-K · ResultsReported its results
  8. May 14, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)
  9. May 15, 2026Insider · 2 peopleInsiders: 5 sales (~$4.1M)
  10. May 22, 2026FDAFDA drug approval: Hepcludex
  11. May 22, 2026Government · Federal Register noticeNotice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
  12. Jun 1, 2026Insider · 1 personInsiders: 3 sales (~$2.0M)
  13. Jun 15, 2026 · this disclosureInsiderOfficer sold ~$133K of GILD shares in the open market

What came next

  1. Jun 15, 2026Insider · 2 peopleInsiders: 3 sales (~$615K)
  2. Jun 24, 2026FDAFDA drug approval: Trodelvy
  3. Jun 24, 2026FDAFDA drug approval: Trodelvy
  4. Jul 1, 2026Insider · 1 personInsiders: 2 sales (~$1.9M)
  5. Jul 15, 2026Insider · 2 peopleInsiders: 2 sales (~$780K)
  6. Aug 3, 2026Insider · 1 personInsiders: 3 sales (~$2.0M)
  7. Aug 4, 2026Company filing · Form 8-K · ResultsReported its results
  8. Aug 17, 2026Insider · 2 peopleInsiders: 3 sales (~$4.3M)
  9. Aug 20, 2026Insider · 1 personInsiders: 5 sales (~$725K)
  10. Aug 26, 2026Insider · 1 personInsiders: 4 sales (~$2.7M)
  11. Aug 27, 2026FDAFDA drug approval: Bixlenvo Sunlenca Starter Pack (Copackaged)
  12. Aug 27, 2026FDAFDA drug approval: Sunlenca
  13. Aug 27, 2026FDAFDA drug approval: Bixlenvo
  14. Aug 27, 2026FDAFDA drug approval: Sunlenca
  15. Sep 1, 2026Insider · 1 personInsiders: 3 sales (~$2.2M)
  16. Sep 15, 2026Insider · 2 peopleInsiders: 4 sales (~$869K)
  17. Oct 1, 2026Insider · 1 personInsiders: 2 sales (~$2.2M)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Gilead Sciences

For Gilead Sciences, OQRO holds 47 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its GILD page.

Other recent filings by Johanna Mercier, Chief Comm & Corp Aff Officer

The full history of Johanna Mercier, Chief Comm & Corp Aff Officer is on the profile page.

How this filing works

Explore the data

Common questions

Which Gilead Sciences (GILD) insider traded, and how much?

Johanna Mercier, Officer at Gilead Sciences, sold ~$133K of Gilead Sciences shares. 1,070 shares at $124.00.

When did it happen, and when was it made public?

Traded: Jun 15, 2026. Filed: Jun 16, 2026. That is 1 day between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Gilead Sciences recently?

For Gilead Sciences, OQRO holds 47 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the GILD page.

Does this mean GILD stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Gilead Sciences

Everything OQRO holds on this company is on its GILD page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data